MIGS | Ophthalmology Innovation Source

Biggest OIS Ever Set to Deliver News & Insights

The maturation and advance of the ophthalmology sector will be fully evident tomorrow as we host the largest Ophthalmology Innovation Summit in its seven-year history. More than 900 clinicians, investors, and executives will descend upon the Planet Hollywood Hotel in Las Vegas to grab a glimpse of novel new treatments for ophthalmology disorders. Three dozen…

Transcend’s Move Toward PMA

Well, the MIGs market could get a little more crowded. This week, Transcend Medical announced it had submitted the final module of its PMA application for the CyPass Micro-Stent, an implant designed to reduce intraocular pressure (IOP) in patients with primary open-angle glaucoma. FDA approval, which likely won’t come until next year at the earlier,…

Sadri: How MIGS And Other New Tech May Change His Practice

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 058″] Ehsan Sadri, MD, FACS, FAAO discusses the impact MIGS will have on ophthalmology practices and offers his insights on how ophthalmologist will handle pressure from Obamacare and other external forces going forward. Transcript: Tom Salemi: Hi, everyone. This is Tom Salemi. I am the host of the OIS Podcast which…

Aquesys’ CEO Details Allergan’s Successful Bid

Last week’s sale of Aquesys represented a homecoming for CEO Ron Bache, who started his surgical device career at Allergan in the late 1990s. However, the decision to sell the privately held MIGS company to the Allergan speaks much more directly to the kind of home Allergan will be for XEN Gel Stent, Aquesys’ entry…

Revenue Report Card for Recent IPO Class

As a rule, medical device companies have to demonstrate some level of commercial viability if they’re going to go public. A few are able to stage an IPO without meaningful revenue. However, most other device companies that have gone public lately have had to prove that customers are buying what they’re selling. And now that…

Newer glaucoma medication classes about to be a reality?

While our podcast this week examines the rise of Glaukos and the MIGs market, contributor Michelle Dalton presents a State of the Glaucoma Drugs address. With no new classes of drugs to treat glaucoma introduced since the mid-1990s, clinicians and Wall Street are waiting for the next “big thing” to hit the market. Reuters places…

CEO Tom Burns Has Even Bigger Plans For Glaukos

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 052″] MIGs leader Glaukos Corp. raised over $100 million in an IPO to expand its already commanding reach in the white hot MIGs Market. Now the company commands a market capitalization close to $1 billion, enriching the venture investors who committed more than $100 million in venture capital to the company.…

Were Glaukos’ IPO Investors Irrationally or Rightly Exuberant?

OIS Hot Shot Glaukos Corp. (NASDAQ—GKOS) raised over $100 million in an initial public offering (IPO) that highlighted extraordinary demand for ophthalmology’s minimally invasive glaucoma surgery (MIGS) market leader. In its initial SEC filing, Glaukos had proposed selling 5.4 million shares in the range $13 to $15 per share. With a positive investor reaction during…

InnFocus

The MicroShunt has just completed enrollment (n=75) in a pivotal study, and is the only device to be directly compared to trabeculectomy. The device has been used in humans for more than 12 years outside the U.S., with mean postop pressures below 14 mmHg. The pressure reduction seen at 3 months holds through 3 years.…

Spotlight on Pressure Reduction

Participants: Kuldev Singh, MD, MPH Dr. Kuldev Singh is Professor of Ophthalmology and Director of the Glaucoma Service at the Stanford University School of Medicine. View Full Profile Thomas A. Mitro Thomas A. Mitro has served as our President and COO since August 2013. From November 2012 to August 2013, Mr. Mitro served as Vice…

Glaukos

The $4.9 billion glaucoma market is expected to reach $6.6 billion by 2019. The company launched its first product, the iStent, about 2 years ago and has had reasonable market penetration. Further, the company has had tremendous success with getting reimbursement for the device. Prior to the introduction of micro-incisional glaucoma surgery (MIGS), surgery was…

Spotlight on MIGS – Market Overview

Participant: Eric Donnenfeld, MD Eric Donnenfeld, MD is a founding partner of Ophthalmic Consultants of Long Island, Professor of Ophthalmology NYU and a Trustee at Dartmouth Medical School. View Full Profile